Aquestive Therapeutics, Inc. (AQST) Free cash flow 2017–2025
Aquestive Therapeutics, Inc. (AQST) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$53.0MFY2025 · since FY2017: $3.8M → -$53.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$53.0M | -47.5% |
| FY2024 | -$35.9M | -387.0% |
| FY2023 | -$7.4M | +32.0% |
| FY2022 | -$10.8M | +68.0% |
| FY2021 | -$33.9M | +26.3% |
| FY2020 | -$46.0M | +24.5% |
| FY2019 | -$60.9M | -310.9% |
| FY2018 | -$14.8M | -494.4% |
| FY2017 | $3.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice